Clinical Trials

Tonix is committed to improving the lives of patients by identifying, researching and developing promising therapies which have the potential to address unmet needs.

TNX-102 SL

Phase III – Fibromyalgia

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TNX-102 SL taken daily at bedtime by patients with Fibromyalgia in 30 locations in the US.

For more information, visit https://clinicaltrials.gov/ (NCT05273749) and https://resilientstudy.com/.

To see if you pre-qualify, please visit https://resilientstudy.com/ and click “See if You Qualify” to find a participating site near you. If no sites are found near you, please try again in a month as some sites may be available later.

Phase II – Long COVID

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TNX-102 SL taken daily at bedtime by patients for the management of multi-site pain associated with Long COVID in 30 locations in the US.

For more information, visit https://clinicaltrials.gov/ (NCT05472090) and https://covidprevailstudy.com/.

To see if you pre-qualify, please visit https://covidprevailstudy.com/ and click “See if You Qualify” to find a participating site near you. If no sites are found near you, please try again in a month as some sites may be available later.

TNX-1900

Phase II – Chronic Migraine

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TNX-1900 taken prophylactically on a daily basis to prevent chronic migraine in 25 locations in the US.

For more information, visit: https://clinicaltrials.gov/ (NCT05679908) and https://migrainepreventionstudy.com/

To see if you pre-qualify, please visit https://migrainepreventionstudy.com/ and click “See if You Qualify” to find a participating site near you. If no sites are found near you, please try again in a month as some sites may be available later.

TNX-601 ER

Phase II – Major Depressive Disorder

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of TNX-601 ER taken daily to treat major depressive disorder in 30 locations in the US.

For more information, visit: https://clinicaltrials.gov/ (NCT05686408).

Patient Resources

The below are a few patient advocacy organizations that provide resources and support to those affected by Fibromyalgia and Long COVID: